|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Underuse of hydralazine/nitrate (HYD/NIT) in black patients with heart failure and reduced ejection fraction (HFrEF) has been previously described, but whether this important treatment gap persists in contemporary practice is unknown.
|
31679641 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Underuse of hydralazine/nitrate (HYD/NIT) in black patients with heart failure and reduced ejection fraction (HFrEF) has been previously described, but whether this important treatment gap persists in contemporary practice is unknown.
|
31679641 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study uncovers a positive role of EDD in docetaxel resistance in prostate cancer, and further links it with the regulation of Wnt/β-Catenin signaling.
|
31472148 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The E3 ubiquitin ligase EDD modifies substrate proteins through ubiquitination and is involved in the regulation of cell proliferation and tumorigenesis.
|
31472148 |
2019 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Altogether, our study uncovers a positive role of EDD in docetaxel resistance in prostate cancer, and further links it with the regulation of Wnt/β-Catenin signaling.
|
31472148 |
2019 |
|
Hormone refractory prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Functionally, EDD knockdown resensitizes HRPC cells to docetaxel in vitro and in vivo, and in reverse, EDD overexpression promotes docetaxel resistance.
|
31472148 |
2019 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
EDD mRNA and protein levels varied in human BCa cell lines.
|
31392083 |
2019 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
EDD mRNA and protein levels varied in human BCa cell lines.
|
31392083 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study showed that EDD immunostaining was low in benign human breast tissues, but increased progressively in ductal carcinoma in-situ, low-grade, and high-grade BCa, and in triple-negative BCa (TNBC).
|
31392083 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
UBR5 overexpression was significantly associated with tumor size, histological and tumor differentiation.
|
30775814 |
2019 |
|
Malignant neoplasm of gallbladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Gallbladder Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Stage 0 Gallbladder Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Stage IIA Gallbladder Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Stage IIB Gallbladder Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Stage III Gallbladder Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Stage IV Gallbladder Cancer AJCC v8
|
0.010 |
Biomarker
|
disease |
BEFREE |
UBR5 may be an important biomarker for predicting the prognosis of patients with GBC.
|
30775814 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Huntington Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Conversely, loss of UBR5 increases HTT levels and triggers polyQ-expanded aggregation in HD-iPSCs.
|
30038412 |
2018 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Results showed circ-UBR5 expression was significantly downregulated in NSCLC tissues (p < 0.001) and was correlated with tumor differentiation (p = 0.00126), suggesting circ-UBR5 might serve as an index of NSCLC differentiation.
|
29944885 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Results showed circ-UBR5 expression was significantly downregulated in NSCLC tissues (p < 0.001) and was correlated with tumor differentiation (p = 0.00126), suggesting circ-UBR5 might serve as an index of NSCLC differentiation.
|
29944885 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HYD-PEP06 is a novel RGD-modified Endostar mimetic peptide with 30 amino acids that is intended to suppress the formation of neoplasm vessels.
|
29935477 |
2018 |
|
Malignant Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Hence, we have established a key role for UBR5 in ciliogenesis that may have important implications in understanding cancer pathophysiology.
|
29742019 |
2018 |
|
Primary malignant neoplasm
|
0.070 |
Biomarker
|
group |
BEFREE |
Hence, we have established a key role for UBR5 in ciliogenesis that may have important implications in understanding cancer pathophysiology.
|
29742019 |
2018 |